CSF1R and cancer: JNJ-40346527 (Edicotinib), a selective inhibitor of colony-stimulating factor-1 receptor (CSF-1R) tyrosine kinase that was originally evaluated for arthritis, inflammatory bowel disease, and cancer is being tested in a phase 1 trial in patients with MCI.